Arrowhead Pharmaceuticals Inc

13 Nov 2026, 21:07 UTC

Arrowhead Pharmaceuticals received an Outperform rating from RBC Capital, maintaining a $100 price target, while Morgan Stanley lowered its target to $106.

12 Nov 2026, 22:02 UTC

Arrowhead Pharmaceuticals reports a net loss of $724.2 million for fiscal year 2026, with revenue of $450.8 million, missing estimates.

11 Nov 2026, 21:12 UTC

Arrowhead Pharmaceuticals, Inc. is trading modestly higher in after-market hours, holding steady with a cumulative return since Wednesday's close.

10 Nov 2026, 23:01 UTC

Arrowhead Pharmaceuticals is trading higher during after-market hours, following significant market gains after the October Consumer Price Index release and rising U.S. household debt.

9 Nov 2026, 22:31 UTC

Arrowhead Pharmaceuticals to participate in upcoming investor conferences, including Jefferies and Citi's Global Healthcare Conferences, conducting fireside chat presentations.

6 Nov 2026, 20:46 UTC

Arrowhead Pharmaceuticals is trading modestly higher after securing a $400 million term loan from Sixth Street to enhance financial flexibility.

5 Nov 2026, 23:16 UTC

Arrowhead Pharmaceuticals, Inc. shares advanced modestly higher during after-market hours on Thursday, despite earlier declines and broader weakness in the biotechnology sector.

4 Nov 2026, 21:52 UTC

Arrowhead Pharmaceuticals, Inc. shares declined modestly during after-market hours on Wednesday, breaking a recent trend of higher daily closes.

3 Nov 2026, 20:46 UTC

Arrowhead Pharmaceuticals, Inc. is trading higher with a modest gain, having reached a session high earlier before pulling back slightly.

2 Nov 2026, 22:01 UTC

Arrowhead Pharmaceuticals, Inc. is trading modestly higher during after-market hours, reflecting the broader market's gains following positive economic data for October.

30 Oct 2026, 20:41 UTC

Arrowhead Pharmaceuticals, Inc. shares declined during after-market hours on Friday, breaking a trend of higher daily closes observed in recent sessions.

29 Oct 2026, 23:26 UTC

Arrowhead Pharmaceuticals, Inc. is trading lower in after-market hours, continuing a downward trend since Thursday's close and reaching its lowest point of the session.

28 Oct 2026, 19:46 UTC

Arrowhead Pharmaceuticals, Inc. is trading higher in Wednesday's market session, reaching a peak return that reflects routine performance for this time of day.

27 Oct 2026, 20:13 UTC

Arrowhead Pharmaceuticals, Inc. is trading modestly higher in after-market hours, reflecting unusual strength.

26 Oct 2026, 22:21 UTC

Arrowhead Pharmaceuticals Inc is trading lower in after-market hours, having declined from a brief return to even since Monday's close.

23 Oct 2026, 20:13 UTC

Arrowhead Pharmaceuticals Inc shares are trading lower in after-hours action, continuing a decline observed over the past three sessions and remaining below its 20-day moving average.

22 Oct 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares are declining, pulling back from an earlier high and trading near the lower end of their one-month range.

21 Oct 2026, 20:07 UTC

Arrowhead Pharmaceuticals' stock declined after reporting interim data from a Phase 1/2a trial for ARO-MAPT, despite promising early results in targeting Alzheimer's disease.

20 Oct 2026, 20:08 UTC

Arrowhead Pharmaceuticals Inc shares advanced during Tuesday's trading session, experiencing a notable early spike before retracing slightly but ultimately closing higher.

16 Oct 2026, 20:07 UTC

Arrowhead Pharmaceuticals shares are declining, with UBS setting a price target of $109 and HC Wainwright at $120 amid concerns over stock performance.

15 Oct 2026, 19:16 UTC

Arrowhead Pharmaceuticals shares are declining despite UBS maintaining a Buy rating with a price target of $109 and H.C. Wainwright setting a higher target of $120.

14 Oct 2026, 22:06 UTC

Arrowhead Pharmaceuticals reports interim results from a Phase 1/2a study of ARO-MAPT for Alzheimer's treatment, with shares advancing in after-market trading.

13 Oct 2026, 22:02 UTC

Arrowhead Pharmaceuticals Inc shares advanced during after-market hours, gaining ground amid caution from social media users ahead of an important call with a key opinion leader.

12 Oct 2026, 22:26 UTC

Arrowhead Pharmaceuticals Inc's shares were roughly flat in after-market trading, significantly below their 20-day moving average after a substantial decline over the past month.

9 Oct 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

8 Oct 2026, 20:07 UTC

Arrowhead Pharmaceuticals announces FDA entry of plozasiran into the Split Real Time Application Review pilot program, despite ongoing declines in its stock price.

6 Oct 2026, 20:00 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply, trading at 62, marking the fifth consecutive session of lower closes and remaining significantly below its 20-day moving average.

5 Oct 2026, 21:20 UTC

Arrowhead Pharmaceuticals Inc shares are advancing in after-market trading, recovering from an earlier dip to reach their highest point of the day amid increased social media attention.

3 Oct 2026, 00:00 UTC

Arrowhead Pharmaceuticals Inc has advanced in after-market trading, recovering from an initial dip and marking a notable recovery since Friday's close.

2 Oct 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares fell modestly, continuing a downward trend with three consecutive sessions finishing lower amid a broader market decline.